The neoadjuvant PD-1 inhibitor nivolumab induced a pathological response in 9 of 20 (45%) resected NSCLC tumors in stages I, II, and IIIA, including both PD-1-positive and -negative tumors, with few side effects [6]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.